The NIMBLE System: A novel non-invasive and non-ionizing medical device for the continous monitoring of patients with implanted cardiovascular stents""""broad
NIMBLE System · Horizon Europe grant · 2024-02-01–2026-07-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2023-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2023-ACCELERATOROPEN-01. CORDIS record →
Objective
At NIMBLE Diagnostics we are developing a first-in-class microwave-based medical device for the non-invasive and non-ionizing monitoring of patients with implanted stents.Stents are one of the most implanted devices worldwide and are used to re-open blocked arteries and restore the correct flow of blood or other fluids. They are especially useful to prevent heart attacks or to treat their lasting symptoms, but, after implantation, become blocked or damaged in 30% of cases. Symptoms only appear after a stent is already 90% dysfunctional, which increases the incidence of serious complications, including strokes, heart attacks or sudden death. Diagnosis of malfunctioning stents is still symptom-driven and is based on an invasive procedure called catheter angiography, involving anesthesia, X-ray exposure and 24h hospitalization recovery. This complex, costly and invasive procedure is not appropriate for ongoing monitoring, which is why the standard of care only reacts when patients already have potentially life-threatening symptoms.The NIMBLE System can read the electromagnetic signature of any stent non-invasively in less than 5 seconds and can be used to provide information on stent status and malfunction during regular clinical visits. Thus, NIMBLE enables early treatments to prevent negative outcomes and personalization of therapy, shifting from reactive to proactive care.Our technology is currently at TRL5/6, with an MVP that has shown excellent results in pre-clinical validations. We have also started the first-in-human testing in a pilot study of 30 patients that will finish early 2024.The EIC Accelerator program will allow us to bridge the biggest risk of our project by performing the regulatory clinical trial to obtain the CE mark, as well as support us to create and access a multi-billion blue ocean market opportunity. This will allow us to establish NIMBLE as a European leader in the future of implant diagnostics and aid millions of patients worldwide.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| NIMBLE DIAGNOSTICS SL | ES | coordinator | €2,306,500 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.